User contributions
From 2012.igem.org
(Latest | Earliest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)
- 15:11, 26 September 2012 (diff | hist) Team:Wageningen UR
- 15:11, 26 September 2012 (diff | hist) Team:Wageningen UR
- 15:09, 26 September 2012 (diff | hist) Team:Wageningen UR/InsideModification (→Introduction)
- 15:02, 26 September 2012 (diff | hist) Team:Wageningen UR/Applications (→Nanomaterials, nanoreactors and more)
- 15:01, 26 September 2012 (diff | hist) Team:Wageningen UR/Applications (→Nanomaterials, nanoreactors and more)
- 15:01, 26 September 2012 (diff | hist) Team:Wageningen UR/Applications (→References)
- 14:59, 26 September 2012 (diff | hist) Team:Wageningen UR/ObtainingthePoleroVLP (→Isolation of the TuYV construct)
- 14:56, 26 September 2012 (diff | hist) Team:Wageningen UR/ObtainingthePoleroVLP (→Read Through part)
- 14:54, 26 September 2012 (diff | hist) Team:Wageningen UR/ObtainingthePoleroVLP
- 14:53, 26 September 2012 (diff | hist) Team:Wageningen UR/ObtainingthePoleroVLP (→Polerovirus Natural BioBrick)
- 14:49, 26 September 2012 (diff | hist) Team:Wageningen UR/Attributions (→Team Achievements)
- 14:39, 26 September 2012 (diff | hist) Team:Wageningen UR/Applications (→Standardized vaccine platforms)
- 14:36, 26 September 2012 (diff | hist) Team:Wageningen UR/Applications (→Standardized vaccine platforms)
- 14:35, 26 September 2012 (diff | hist) Team:Wageningen UR/Applications (→Standardized vaccine platforms)
- 14:35, 26 September 2012 (diff | hist) Team:Wageningen UR/Applications (→Standardized vaccine platforms)
- 14:33, 26 September 2012 (diff | hist) Team:Wageningen UR/Applications (→Standardized vaccine platforms)
- 14:30, 26 September 2012 (diff | hist) N File:Table 1. Examples of VLPs used for vaccines and vaccine development.jpg (top)
- 14:30, 26 September 2012 (diff | hist) Team:Wageningen UR/Applications (→Standardized vaccine platforms)
- 14:00, 26 September 2012 (diff | hist) Team:Wageningen UR/ObtainingthePoleroVLP (→Read Through part)
- 13:59, 26 September 2012 (diff | hist) Team:Wageningen UR/ObtainingthePoleroVLP (→Results)
- 13:58, 26 September 2012 (diff | hist) Team:Wageningen UR/ModifyingtheHepatitisB (→Methods)
- 13:58, 26 September 2012 (diff | hist) Team:Wageningen UR/ModifyingtheHepatitisB (→Methods)
- 13:44, 26 September 2012 (diff | hist) Team:Wageningen UR/Applications (→Nanomaterials, nanoreactors and more)
- 13:43, 26 September 2012 (diff | hist) Team:Wageningen UR/Applications (→Nanomaterials, nanoreactors and more)
- 13:43, 26 September 2012 (diff | hist) Team:Wageningen UR/Applications (→Nanomaterials, nanoreactors and more)
- 13:36, 26 September 2012 (diff | hist) Team:Wageningen UR/Applications (→Site-specific drug delivery)
- 13:35, 26 September 2012 (diff | hist) N File:Fajiofjdodjasoijdisjfdj.jpg (top)
- 13:34, 26 September 2012 (diff | hist) Team:Wageningen UR/Applications (→Nanomaterials, nanoreactors and more)
- 13:33, 26 September 2012 (diff | hist) Team:Wageningen UR/Applications (→Nanomaterials, nanoreactors and more)
- 13:33, 26 September 2012 (diff | hist) Team:Wageningen UR/Applications (→Nanomaterials, nanoreactors and more)
- 13:32, 26 September 2012 (diff | hist) Team:Wageningen UR/Applications (→Site-specific drug delivery)
- 13:28, 26 September 2012 (diff | hist) Team:Wageningen UR/Applications (→Site-specific drug delivery)
- 13:27, 26 September 2012 (diff | hist) Team:Wageningen UR/Applications (→Site-specific drug delivery)
- 13:26, 26 September 2012 (diff | hist) Team:Wageningen UR/Applications (→Site-specific drug delivery)
- 13:25, 26 September 2012 (diff | hist) Team:Wageningen UR/Applications (→Site-specific drug delivery)
- 13:22, 26 September 2012 (diff | hist) N File:Producing site-specific drug delivery system using VLPs.jpg (top)
- 13:21, 26 September 2012 (diff | hist) Team:Wageningen UR/Applications (→Site-specific drug delivery)
- 13:19, 26 September 2012 (diff | hist) Team:Wageningen UR/Applications (→Site-specific drug delivery)
- 11:19, 26 September 2012 (diff | hist) Team:Wageningen UR/OutsideModification (→Polerovirus)
- 11:17, 26 September 2012 (diff | hist) Team:Wageningen UR/OutsideModification (→Hepatitis B)
- 11:16, 26 September 2012 (diff | hist) Team:Wageningen UR/OutsideModification (→Hepatitis B)
- 11:15, 26 September 2012 (diff | hist) Team:Wageningen UR/OutsideModification (→Hepatitis B)
- 11:15, 26 September 2012 (diff | hist) Team:Wageningen UR/OutsideModification (→Polerovirus)
- 11:12, 26 September 2012 (diff | hist) Team:Wageningen UR/OutsideModification (→Polerovirus)
- 11:10, 26 September 2012 (diff | hist) Team:Wageningen UR/OutsideModification (→Polerovirus)
- 11:07, 26 September 2012 (diff | hist) Team:Wageningen UR/OutsideModification (→Polerovirus)
- 11:06, 26 September 2012 (diff | hist) Team:Wageningen UR/OutsideModification (→PLRV and TuYV)
- 11:04, 26 September 2012 (diff | hist) Team:Wageningen UR/OutsideModification (→PLRV and TuYV)
- 11:04, 26 September 2012 (diff | hist) Team:Wageningen UR/OutsideModification (→PLRV and TuYV)
- 11:03, 26 September 2012 (diff | hist) N File:.TuYV monomer with readthrough or without readthrough.jpg
(Latest | Earliest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)